GRIFOLS SA (GRFS)
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
📈 **POSITIVE** • Medium confidence analysis (78%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (93%) **Content type:** Clinical